Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas
Authors
Keywords
-
Journal
JOURNAL OF DRUG TARGETING
Volume -, Issue -, Pages 1-6
Publisher
Informa UK Limited
Online
2021-05-21
DOI
10.1080/1061186x.2021.1904248
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Challenges to curing primary brain tumours
- (2019) Kenneth Aldape et al. Nature Reviews Clinical Oncology
- RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
- (2019) Pedro Cabrales Translational Oncology
- REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer
- (2019) Bryan Oronsky et al. Future Oncology
- ATIM-46. A MULTICENTER, PHASE I, TRIAL OF RADIATION, TEMOZOLOMIDE AND RRx-001 FOLLOWED BY MAINTENANCE TEMOZOLOMIDE WITH OR WITHOUT RRx-001 IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
- (2019) Robert Aiken et al. NEURO-ONCOLOGY
- Brain malignancies: Glioblastoma and brain metastases
- (2019) Tamara T. Lah et al. SEMINARS IN CANCER BIOLOGY
- Brain Tumors: Challenges and Opportunities to Cure
- (2017) Ingo K. Mellinghoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial
- (2016) Michelle M. Kim et al. Translational Oncology
- RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
- (2016) Bryan Oronsky et al. Clinical Epigenetics
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme
- (2015) Amanda Tivnan et al. Frontiers in Neuroscience
- Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy—A Review
- (2014) Bryan T. Oronsky et al. Translational Oncology
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors
- (2012) Jan Scicinski et al. CANCER RESEARCH
- Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials
- (2012) S. Ning et al. CANCER RESEARCH
- Coagulation and cancer: biological and clinical aspects
- (2012) A. FALANGA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Development of a Safe and Efficient Two-Step Synthesis for Preparing 1-Bromoacetyl-3,3-dinitroazetidine, a Novel Clinical Anticancer Candidate
- (2012) Nicholas A. Straessler et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Vessel abnormalization: another hallmark of cancer?Molecular mechanisms and therapeutic implications
- (2010) Katrien De Bock et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- New strategies to deliver anticancer drugs to brain tumors
- (2009) Valentino Laquintana et al. Expert Opinion on Drug Delivery
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started